Drugs / GDX012
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05001451 | Aug 2021 → Jun 2022 | acute myeloid leukemia | GammaDelta Therapeutics Limited | Terminated | No outcome recorded Stop: Business |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05886491 | Jul 2023 → Aug 2025 | leukemia | Takeda | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GDX012 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05886491 ↗ |
| Modality | Cell therapy | “Allogeneic cell therapy that is enriched for Vδ1+ γδ T cells” NCT05001451 ↗ |
| Route | Intravenous | “GDX012 Suspension for IV Infusion” NCT05001451 ↗ |